Live Earnings Conference Call: IQVIA will host a live Q3 2026 earnings call on October 27, 2026 at 9:00AM ET. Follow this link to get details and listen to IQVIA's Q3 2026 earnings call when it goes live. Get details. Most-Upgraded StocksMost-UpgradedNYSE:IQV IQVIA (IQV) Stock Price, News & Analysis $273.80 -5.56 (-1.99%) Closing price 10/26/2026 03:59 PM EasternExtended Trading$278.39 +4.59 (+1.67%) As of 07:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About IQVIA Stock (NYSE:IQV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IQVIA alerts:Sign Up Key Stats Today's Range$270.92▼$281.8450-Day Range$236.18▼$279.4752-Week Range$154.50▼$282.98Volume1.69 million shsAverage Volume1.32 million shsMarket Capitalization$45.07 billionP/E Ratio33.97Dividend YieldN/APrice Target$278.75Consensus RatingModerate Buy Company Overview IQVIA Holdings Inc. is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services. Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions. IQVIA also supports sales, marketing and market-access activities through data-driven tools and services designed for pharmaceutical companies, healthcare providers and other industry participants. The company was formed through the 2016 merger of Quintiles Transnational Holdings and IMS Health and adopted the IQVIA name in 2017. It serves customers across North America, Europe, Asia-Pacific, Latin America, the Middle East and Africa. IQVIA is led by Chairman and Chief Executive Officer Ari Bousbib.AI Generated. May Contain Errors. Read More IQVIA Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreIQV MarketRank™: 4.17066839714 of 5 starsIQVIA scored higher than 83% of companies evaluated by MarketBeat, and ranked 89th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.6 / 5Analyst RatingModerate Buy Consensus RatingIQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 16 buy ratings, 4 hold ratings, and no sell ratings.Upside/DownsideThe consensus price target for IQVIA is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageIQVIA has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IQVIA's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth11.70% Earnings GrowthEarnings for IQVIA are expected to grow by 11.70% in the coming year, from $11.54 to $12.89 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IQVIA is 24.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.87.Price to Earnings Ratio vs. SectorThe P/E ratio of IQVIA is 24.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.Price to Earnings Growth RatioIQVIA has a PEG Ratio of 2.46. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIQVIA has a P/B Ratio of 7.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IQVIA's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.85% of the float of IQVIA has been sold short.Short Interest Ratio / Days to CoverIQVIA has a short interest ratio ("days to cover") of 2.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in IQVIA has recently decreased by 6.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIQVIA does not currently pay a dividend.Dividend GrowthIQVIA does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.04 News SentimentIQVIA has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 14 news articles for IQVIA this week, compared to 6 articles on an average week.Search Interest8 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added IQVIA to their MarketBeat watchlist in the last 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, IQVIA insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,796,021.00 in company stock.Percentage Held by Insiders1.70% of the stock of IQVIA is held by insiders.Percentage Held by Institutions89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IQVIA's insider trading history. Receive IQV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IQV Stock News HeadlinesIQVIA (IQV) Projected to Announce Quarterly Earnings on TuesdayOctober 26 at 4:27 AM | americanbankingnews.comIQVIA (IQV) Q3 earnings report preview: what to look forOctober 26 at 3:15 AM | msn.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December.October 27 at 1:00 AM | Porter & Company (Ad)Josh Brown's best stocks in the market: IQVIAOctober 24 at 10:28 AM | msn.comFrom Headwinds to Full Valuation: The Disciplined Exit of IQVIA Holdings (IQV)October 23, 2026 | insidermonkey.comLocking in Gains: Portfolio Discipline Triggers IQVIA Holding (IQV) Trim After Q2 BeatOctober 23, 2026 | insidermonkey.comJosh Brown's 'Best Stocks in the Market:' IQVIAOctober 22, 2026 | cnbc.comIQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires ExecutionOctober 20, 2026 | seekingalpha.comSee More Headlines IQV Stock Analysis - Frequently Asked Questions How have IQV shares performed this year? IQVIA's stock was trading at $225.40 at the beginning of the year. Since then, IQV shares have increased by 21.5% and is now trading at $273.8030. How were IQVIA's earnings last quarter? IQVIA Holdings Inc. (NYSE:IQV) announced its earnings results on Tuesday, July, 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.03 by $0.12. The firm's quarterly revenue was up 8.7% compared to the same quarter last year. Read the conference call transcript. Is IQVIA buying back stock? IQVIA's board authorized a stock buyback plan on Thursday, May 7th 2026, which permits the company to repurchase $2 billion in shares, according to EventVestor. This means that the company could repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company's leadership believes its stock is undervalued. Does IQVIA have any subsidiaries? IQVIA subsidiaries include these companies: Q2 Solutions, Linguamatics, Advanced Health Media LLC, DrugDev, Aileron Solutions, Novella Clinical LLC, 159 Solutions LLC, and others. When did IQVIA IPO? IQVIA (IQV) raised $900 million in an initial public offering (IPO) on Thursday, May 9th 2013. The company issued 23,684,210 shares at $36.00-$40.00 per share. Who are IQVIA's major shareholders? Top institutional investors of IQVIA include Assenagon Asset Management S.A. (0.20%), Artemis Investment Management LLP (0.18%), Vontobel Holding Ltd. (0.17%) and Robeco Institutional Asset Management B.V. (0.09%). Insiders that own company stock include Ari Bousbib, Eric Sherbet, W Richard Staub, James G Berkshire, Kevin C Knightly, Keriann Cherofsky, Bhavik Patel and John G Danhakl. View institutional ownership trends. How do I buy shares of IQVIA? Shares of IQV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of IQVIA own? Based on aggregate information from My MarketBeat watchlists, some other companies that IQVIA investors own include NVIDIA (NVDA), Salesforce (CRM), PayPal (PYPL), Tesla (TSLA), Walt Disney (DIS), Adobe (ADBE) and Visa (V). Company Calendar Last Earnings7/28/2026Today10/27/2026Next Earnings (Estimated)10/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 IQV's financial health is in the Green zone, according to TradeSmith. IQV has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:IQV CIK1478242 Webwww.iqvia.com Phone(919) 998-2000FaxN/AEmployees93,000Year Founded2016Price Target and Rating Average Price Target for IQVIA$278.75 High Price Target$345.00 Low Price Target$174.00 Potential Upside/Downside+1.8%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)$8.06 Trailing P/E Ratio33.97 Forward P/E Ratio23.73 P/E Growth2.46Net Income$1.36 billion Net Margins8.10% Pretax Margin9.27% Return on Equity30.25% Return on Assets6.54% Debt Debt-to-Equity Ratio2.18 Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$16.31 billion Price / Sales2.76 Cash Flow$17.51 per share Price / Cash Flow15.64 Book Value$38.93 per share Price / Book7.03Miscellaneous Outstanding Shares164,600,000Free Float161,802,000Market Cap$45.07 billion OptionableOptionable Beta1.17 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NYSE:IQV) was last updated on 10/26/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IQVIA Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IQVIA With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
